Last reviewed · How we verify
NCT03324256
Energy Drinks and Vascular Function
NA trial testing energy drink in Vascular Function in 19 participants. Completed in 16 May 2019.
16 May 2019
Quick facts
| Lead sponsor | University of Florida |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 19 |
| Start date | 12 January 2018 |
| Primary completion | 16 May 2019 |
| Estimated completion | 16 May 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- energy drink
- caffeinated drink
- Energy gum
- placebo gum — full drug profile →
- Control drink
- Total sleep deprivation
Conditions studied
- Vascular Function — all drugs for Vascular Function →
Sponsor
University of Florida
Who can join
Adults 18 to 30, male only, with Vascular Function. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study will be to examine the acute effect of commercially available energy products on endothelial function, arterial stiffness and thrombosis in healthy young males.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03324256
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of energy drink
Trials testing the same drug.
- NCT04961086 — Health Effect of Energy Drink Consumption · NA · completed
- NCT04727905 — The Effect of Supplementing Different Solutions on Firefighters' Simulated Fire Rescue Training · NA · completed
- NCT03021616 — Evaluation of Energy Drinks on Electrocardiographic, Vascular and Hematologic Parameters in Healthy Volunteers · NA · terminated
Other recruiting trials for Vascular Function
Currently open trials in the same condition.
- NCT06823570 — Anti-hypertensive Therapy and Exercise Treatment to Improve Vascular Health in Patients With Hypertension. · NA · recruiting
- NCT06128278 — Acute Equol Supplementation and Vascular Function in Women With and Without CKD · Phase 2 · recruiting
- NCT05468255 — The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active Adults · NA · recruiting
Other University of Florida trials
Trials by the same sponsor.
- NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
- NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
- NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
- NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
- NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03324256 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Florida
- Last refreshed: 20 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03324256.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing